Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Short Interest Update

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) was the recipient of a significant drop in short interest during the month of April. As of April 30th, there was short interest totaling 13,319 shares, a drop of 78.7% from the April 15th total of 62,619 shares. Approximately 0.1% of the company’s stock are short sold. Based on an average daily trading volume, of 42,961 shares, the days-to-cover ratio is currently 0.3 days.

Genenta Science Stock Down 4.3%

Genenta Science stock traded down $0.03 during midday trading on Wednesday, hitting $0.59. 59,586 shares of the stock were exchanged, compared to its average volume of 49,739. Genenta Science has a 52-week low of $0.56 and a 52-week high of $10.00. The business’s 50-day moving average price is $0.73 and its 200-day moving average price is $1.30. The company has a quick ratio of 14.16, a current ratio of 14.16 and a debt-to-equity ratio of 0.35.

Genenta Science (NASDAQ:GNTA) last released its earnings results on Tuesday, March 31st. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.28.

Institutional Trading of Genenta Science

Several hedge funds and other institutional investors have recently modified their holdings of GNTA. SmartHarvest Portfolios LLC bought a new stake in Genenta Science during the 4th quarter worth approximately $26,000. Citadel Advisors LLC bought a new stake in Genenta Science during the 3rd quarter worth approximately $41,000. Alyeska Investment Group L.P. bought a new stake in Genenta Science during the 4th quarter worth approximately $328,000. Norges Bank bought a new stake in Genenta Science during the 4th quarter worth approximately $337,000. Finally, Weiss Asset Management LP bought a new stake in Genenta Science during the 4th quarter worth approximately $480,000. Institutional investors own 15.13% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Genenta Science in a report on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

About Genenta Science

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.